TGFB2 and Hepatic fibrosis: In this paper, we describe successful experiments aimed at generating specific antibodies against the two degradation products of LAP (LAP-DP) produced after PLK digestion, and the use of these antibodies to stain the LAP-DP in patient livers, thereby providing evidence of PLK-dependent TGF-β1 activation in human hepatic fibrosis.